Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07551440

Identification of Therapeutic Targets in Metastatic Gastric Cancer

This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Stomach Neoplasms, Benign Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasm Metastasis Neoplasms Neoplasms by Site Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Stomach Diseases Stomach Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Chinese University of Hong Kong

Hong Kong, 0000

Location status: Recruiting

Location contact

Shannon Chan

CONTACT

[email protected]

35052627

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients age >= 18, <= 80 years old
  • Performance status (WHO) <=2
  • Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases
  • Patients with isolated ovarian metastasis could be included
  • Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
  • Ability to give written consent before the commencement of treatment

Exclusion criteria

  • Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy
  • Pregnancy or breastfeeding
  • Patients with irreversible coagulation disorders

Treatment and study plan

Primary outcomes

  1. Biobank construction

    Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.

    Recruit patients and collect the required biological samples (i.e. tumor tissues, blood and ascites samples) for biobank construction.

  2. Detection of noval therapeutic targets for treating gastric cancer cancer with metastases.

    Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.

    Biological samples (i.e. tissue, blood and ascites samples) collected from enrolled patients will be used in genome and transcriptome analysis using next generation sequencing, DNA mutation detection using digital PCR and mass spectrometry-based proteomic.

  3. Organoid culture for drug sensitivity assay

    Time frame: Collect at baseline(pre-treatment) and/or during interval surgery if clinically indicated and/or after completing all systemic and surgical treatment if patient required an endoscopy or laparoscopy due to clinical need only.

    Gastric tumor tissues are collected from enrolled patients to establish patient-derived organoids and subject to drug sensitivity assay. The choice of drugs will depend on the molecular analysis results and will be advised by oncologists.

Secondary outcomes

  1. Clinical Outcome - Overall survival

    Time frame: through study completion, an average of 5 year

    Patients' overall survival will also be recorded.

  2. Clinical Outcome - Progression-free survival

    Time frame: through study completion, an average of 5 year

    Patients' progression-free survival will also be recorded.

  3. Clinical Outcome - Karnofsky Score

    Time frame: At baseline measurement

    Karnofsky Score for measuring quality of life will be recorded

  4. Clinical Outcome - Time point of metastasis

    Time frame: Recruitment till death or 5 year

    Patients' time point of metastasis, whether it is synchronous or metachronous will be recorded

  5. Clinical Outcome - Number of previous chemotherapy/ target therapy/ immunotherapy

    Time frame: Measured and asked at baseline

    Number of previous chemotherapy/ target therapy/ immunotherapy received by the patients will be recorded

  6. Clinical Outcome - Presence of ascites

    Time frame: Recruitment till death or 5 year

    Presence of ascites on recruited patients will be recorded

  7. Clinical Outcome - Cancer Restaging

    Time frame: Post-treatment till death or 5 year

    Stage of cancer will be recorded and determined with CT/PETCT scan

Study contacts

Contact information is provided by the study sponsor or research team.

Shannon Melissa Chan, PhD

CONTACT

[email protected]

35052627

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

Identification of Novel Therapeutic Targets in Gastric Cancer With Lymph Node or Distant Metastasis: An Explorative Study

Important dates

Study start
2023
Primary completion
2033
Study completion
2033
First posted
Apr 24, 2026
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.